source
- Study finds malaria antibody L9LS reduces vaccine response in infantsResearchers in Mali tested the monoclonal antibody L9LS in infants to see if it could protect against malaria and complement the R21 vaccine. The trial showed L9LS provided about 78% protection ov…
- Actinogen’s Alzheimer’s drug Xanamem fails pivotal trial, shares plunge over 80%Actinogen Medical, an Australian biotech, reported that its only candidate, Xanamem (emestedastat), did not meet the primary endpoint in a Phase 2b/3 study in patients with mild to moderate Alzheim…